Date: 2015-12-14
Type of information: Establishment of a new subsidiary in the EU
Compound:
Company: RuiYi, now Bird Rock Bio (USA - CA)
Therapeutic area:
Type agreement: name change
Action mechanism:
Disease:
Details: * On December 14, 2015, Bird Rock Bio announced its corporate name change from RuiYi, Inc. to Bird Rock Bio. The change is expected to be finalized by January 1, 2016. “With the advancement of gerilimzumab into Phase 2 for rheumatoid arthritis (RA) and RYI-018 into Phase 1 for non-alcoholic fibrotic liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH) in 2016, our organization has shifted dramatically from discovery operations in Shanghai to global clinical development for novel antibody therapeutics targeting large unmet medical needs,” said Paul Grayson, CEO.
Financial terms:
Latest news:
